A Randomized Phase III trial of an Endostatin Gene therapy (E10A) combined with chemotherapy and chemotherapy alone for the treatment of head and neck cancer

Trial Profile

A Randomized Phase III trial of an Endostatin Gene therapy (E10A) combined with chemotherapy and chemotherapy alone for the treatment of head and neck cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Endostatin gene therapy (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2015 According to a media release of Marsala Biotech Inc. this trial completed Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the treatment of head and neck cancer.
    • 30 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top